BB.SHR-(D6Rat184-D6Rat3)/K |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
blood triglyceride amount |
female |
84 days
| 24 |
|
106.2 |
mg/dl |
9.57 |
46.9 |
automated blood analysis |
opthalmic venous plexus |
|
0 |
|
|
12988 |
324 |
BN/Seac |
serum triglyceride level |
control condition |
Asahina M, et al., J Lipid Res 2005 Aug 1 |
blood triglyceride amount |
male |
28 days
| 11 |
|
108.0 |
mg/dl |
5.9 |
19.57 |
serum triglyceride analysis |
|
|
0 |
Wako Pure Chemicals, Tokyo, Japan |
|
13139 |
71 |
WOKW/K |
serum triglyceride level |
control condition |
Kovacs P, et al., Biochem Biophys Res Commun 2000 Mar 24;269(3):660-5. |
blood triglyceride amount |
not specified |
196 days-224 days |
12 |
|
287.61 |
mg/dl |
19.16 |
66.37 |
automated serum analysis |
|
0.0 |
0 |
|
|
69114 |
1123 |
BB.SHR-(D6Rat184-D6Rat3)/K |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
blood triglyceride amount |
male |
84 days
| 17 |
|
132.74 |
mg/dl |
9.01 |
37.17 |
automated blood analysis |
opthalmic venous plexus |
0.0 |
0 |
|
|
70105 |
324 |
BB.SHR-(Gnal-D18Mit9)/K |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
blood triglyceride amount |
male |
84 days
| 15 |
|
159.29 |
mg/dl |
9.83 |
38.05 |
automated blood analysis |
opthalmic venous plexus |
0.0 |
0 |
|
|
70107 |
324 |
F344.ZUC-Leprfa/Tj |
serum triglyceride level |
control condition |
Kotoh J, et al., J Vet Med Sci. 2016 Aug 11. |
blood triglyceride amount |
male |
175 days
| 7 |
|
2420.6 |
mg/dl |
316.29 |
836.82 |
serum triglyceride analysis |
|
0.0 |
0 |
TG-E test kit (Wako Chem. LTD) |
|
98078 |
1978 |
SD-Apoeem1Sage |
serum triglyceride level |
control condition |
Ekuni D, et al., Lipids Health Dis. 2014 Sep 5;13:144. doi: 10.1186/1476-511X-13-144. |
blood triglyceride amount |
male |
56 days
| 7 |
|
48.5 |
mg/dl |
4.69 |
12.4 |
high-performance liquid chromatography |
|
0.0 |
0 |
|
|
104497 |
2968 |
GK/Jcl |
serum triglyceride level |
control condition |
Mizukami H, et al., Pancreas. 2013 Jul;42(5):786-94. doi: 10.1097/MPA.0b013e318287c9b5. |
blood triglyceride amount |
male |
154 days
| 7 |
|
158.41 |
mg/dl |
17.7 |
46.83 |
solid phase colorimetry |
|
0.0 |
0 |
|
|
110227 |
3167 |
SHR/Mol |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
blood triglyceride amount |
female |
84 days-98 days |
12 |
|
150.44 |
mg/dl |
5.11 |
17.7 |
automated blood analysis |
opthalmic plexus |
|
0 |
mean of samples at 12, 13 and 14 weeks |
|
12933 |
323 |
SS.SHR-(D2Rat61-D2Mco18)/Mco |
serum triglyceride level |
control condition (for 140 days) |
Garrett MR, et al., Physiol Genomics. 2007 May 15;. |
blood triglyceride amount |
male |
140 days
| 6 |
|
90.9 |
mg/dl |
7.5 |
18.37 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
67986 |
834 |
ExHC/Seac |
serum triglyceride level |
control condition |
Asahina M, et al., J Lipid Res 2005 Aug 1 |
blood triglyceride amount |
male |
28 days
| 7 |
|
98.0 |
mg/dl |
7.3 |
19.31 |
serum triglyceride analysis |
|
|
0 |
Wako Pure Chemicals, Tokyo, Japan |
|
11314 |
71 |
F344.OLETF-(D8Rat58-D8Mgh17)/Tj |
serum triglyceride level |
control condition |
Kose H, et al., Exp Anim. 2008 Apr;57(2):135-8. |
blood triglyceride amount |
male |
217 days
| 20 |
|
167.8 |
mg/dl |
15.3 |
68.42 |
serum triglyceride analysis |
|
0 |
0 |
|
|
66183 |
716 |
WOKW |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 1;284(1):150-6. |
blood triglyceride amount |
female |
196 days-224 days |
12 |
serial mean |
44.25 |
mg/dl |
|
|
automated blood analysis |
ophthalmic venous plexus |
0.0 |
0 |
Roche Cobas Mira Plus (Roche, Switzerland) |
average of measures taken at 196 days, 210 days and 224 days |
12428 |
251 |
MWF/FubRkb |
serum triglyceride level |
control condition |
Schulz A, et al., J Am Soc Nephrol. 2007 Jan;18(1):113-21 |
blood triglyceride amount |
not specified |
168 days
| 18 |
|
95.58 |
mg/dl |
11.5 |
48.81 |
serum triglyceride analysis |
|
0.0 |
0 |
serum triglyceride analysis |
|
65386 |
117 |
DA/K |
serum triglyceride level |
control condition |
Kovacs P, et al., Biochem Biophys Res Commun 2000 Mar 24;269(3):660-5. |
blood triglyceride amount |
not specified |
196 days-224 days |
12 |
|
48.67 |
mg/dl |
2.04 |
7.08 |
automated serum analysis |
|
0.0 |
0 |
|
|
69115 |
1123 |
F344/NSlc |
serum triglyceride level |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
blood triglyceride amount |
male |
168 days-175 days |
7 |
|
130.17 |
mg/dl |
15.88 |
42.01 |
serum triglyceride analysis |
|
0.0 |
0 |
TG-E test kits, Wako Chem. Ltd. Osaka, Japan |
|
97750 |
1918 |
F344.ZUC-Leprfa/Tj |
serum triglyceride level |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
blood triglyceride amount |
male |
168 days-175 days |
10 |
|
2342.86 |
mg/dl |
269.19 |
851.25 |
serum triglyceride analysis |
|
0.0 |
0 |
TG-E test kits, Wako Chem. Ltd. Osaka, Japan |
|
97752 |
1918 |
BB.SHR-(D4Mit6-Spr)/K |
serum triglyceride level |
control condition |
Kovacs P and Kloting I, Arch Biochem Biophys 1998 Jun 1;354(1):139-43. |
blood triglyceride amount |
male |
84 days
| 0 |
|
176.99 |
mg/dl |
|
35.4 |
automated blood analysis |
|
0.0 |
0 |
|
|
106820 |
1034 |
Hsd:SD |
serum triglyceride level |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
blood triglyceride amount |
male |
84 days
| 5 |
|
156.8 |
mg/dl |
12.9 |
28.85 |
automated serum analysis |
|
|
0 |
|
|
106402 |
3025 |
SD-Ahrem2Sage |
serum triglyceride level |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
blood triglyceride amount |
female |
84 days
| 4 |
|
105.7 |
mg/dl |
28.1 |
56.2 |
automated serum analysis |
|
|
0 |
|
|
106405 |
3025 |
SHR/FubRkb |
serum triglyceride level |
control condition |
Schulz A, et al., J Am Soc Nephrol. 2007 Jan;18(1):113-21 |
blood triglyceride amount |
not specified |
168 days
| 10 |
|
61.95 |
mg/dl |
3.54 |
11.19 |
serum triglyceride analysis |
|
0.0 |
0 |
serum triglyceride analysis |
|
65384 |
117 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
serum triglyceride level |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
blood triglyceride amount |
male |
168 days-175 days |
7 |
|
80.54 |
mg/dl |
8.04 |
21.27 |
serum triglyceride analysis |
|
0.0 |
0 |
TG-E test kits, Wako Chem. Ltd. Osaka, Japan |
|
97751 |
1918 |
FHH/EurMcwi |
serum triglyceride level |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
blood triglyceride amount |
male |
112 days
| 6 |
|
37.0 |
mg/dl |
5.3 |
12.98 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
99509 |
2318 |
BB.SHR-(Gnal-D18Mit9)/K |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
blood triglyceride amount |
female |
84 days
| 10 |
|
168.14 |
mg/dl |
20.99 |
66.37 |
automated blood analysis |
opthalmic venous plexus |
0.0 |
0 |
|
|
70108 |
324 |
Jcl:WI |
serum triglyceride level |
control condition |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
blood triglyceride amount |
male |
52 days
| 6 |
|
75.06 |
mg/dl |
6.98 |
17.1 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
103958 |
2884 |
GK/Jcl |
serum triglyceride level |
control condition |
Akiyama S, et al., Biosci Biotechnol Biochem. 2009 Dec;73(12):2779-82. doi: 10.1271/bbb.90576. Epub 2009 Dec 7. |
blood triglyceride amount |
male |
52 days
| 6 |
|
114.12 |
mg/dl |
14.21 |
34.81 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
103959 |
2884 |
SS.ZUC-Leprfa+/+/Slc |
serum triglyceride level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood triglyceride amount |
male |
91 days
| 8 |
|
54.5 |
mg/dl |
9.5 |
26.87 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
101849 |
2641 |
SHRSP/A3N |
serum triglyceride level |
control condition |
Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. |
blood triglyceride amount |
female |
120 days-140 days |
24 |
|
92.0 |
mg/dl |
7.0 |
34.29 |
automated serum analysis |
|
0.0 |
0 |
|
|
107622 |
3093 |
SS/JrTol |
serum triglyceride level |
control condition (for 140 days) |
Garrett MR, et al., Physiol Genomics. 2007 May 15;. |
blood triglyceride amount |
male |
140 days
| 6 |
|
106.1 |
mg/dl |
8.5 |
20.82 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
67984 |
834 |
SS.ZUC-Leprfa-/-/Slc |
serum triglyceride level |
control condition |
Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. |
blood triglyceride amount |
male |
91 days
| 7 |
|
1885.5 |
mg/dl |
325.31 |
860.69 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
101851 |
2641 |
FHH-Nr4a1m1Mcwi |
serum triglyceride level |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
blood triglyceride amount |
male |
56 days
| 6 |
|
192.0 |
mg/dl |
43.3 |
106.06 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
99512 |
2318 |
F344/NSlc |
serum triglyceride level |
control condition |
Kose H, et al., Exp Anim. 2008 Apr;57(2):135-8. |
blood triglyceride amount |
male |
217 days
| 9 |
|
122.4 |
mg/dl |
25.3 |
75.9 |
serum triglyceride analysis |
|
0 |
0 |
|
|
66182 |
716 |
SHR/Mol |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 29;284(5):1126-33. |
blood triglyceride amount |
male |
84 days-98 days |
12 |
|
97.35 |
mg/dl |
2.55 |
8.85 |
automated blood analysis |
opthalmic plexus |
|
0 |
mean of samples at 12, 13 and 14 weeks |
|
12934 |
323 |
BB/OK |
serum triglyceride level |
control condition |
Kovacs P and Kloting I, Arch Biochem Biophys 1998 Jun 1;354(1):139-43. |
blood triglyceride amount |
male |
84 days
| 0 |
|
132.74 |
mg/dl |
|
53.1 |
automated blood analysis |
|
0.0 |
0 |
|
|
68959 |
1034 |
SHR/NHsdMco |
serum triglyceride level |
control condition (for 140 days) |
Garrett MR, et al., Physiol Genomics. 2007 May 15;. |
blood triglyceride amount |
male |
140 days
| 6 |
|
63.0 |
mg/dl |
7.5 |
18.37 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
67985 |
834 |
F344.ZUC-(Leprfa),OLETF-(D14Rat23-D14Rat12)/Tj |
serum triglyceride level |
control condition |
Sasaki D, et al., Mamm Genome. 2015 Dec;26(11-12):619-29. doi: 10.1007/s00335-015-9597-4. Epub 2015 Aug 22. |
blood triglyceride amount |
male |
168 days-175 days |
10 |
|
1240.6 |
mg/dl |
209.56 |
662.69 |
serum triglyceride analysis |
|
0.0 |
0 |
TG-E test kits, Wako Chem. Ltd. Osaka, Japan |
|
97753 |
1918 |
FHH-Nr4a1m1Mcwi |
serum triglyceride level |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
blood triglyceride amount |
male |
56 days
| 6 |
|
82.0 |
mg/dl |
12.6 |
30.86 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
99510 |
2318 |
Jcl:WI |
serum triglyceride level |
control condition |
Mizukami H, et al., Pancreas. 2013 Jul;42(5):786-94. doi: 10.1097/MPA.0b013e318287c9b5. |
blood triglyceride amount |
male |
154 days
| 7 |
|
312.39 |
mg/dl |
22.12 |
58.53 |
solid phase colorimetry |
|
0.0 |
0 |
|
|
110225 |
3167 |
SHRSP/A3N |
serum triglyceride level |
control condition |
Wexler BC, Stroke. 1980 Nov-Dec;11(6):665-71. doi: 10.1161/01.str.11.6.665. |
blood triglyceride amount |
male |
120 days-140 days |
24 |
|
97.0 |
mg/dl |
5.0 |
24.49 |
automated serum analysis |
|
0.0 |
0 |
|
|
107620 |
3093 |
BB.SHR-(D6Rat184-D6Rat3)/K |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
blood triglyceride amount |
male |
84 days
| 22 |
|
141.59 |
mg/dl |
13.4 |
62.83 |
automated blood analysis |
opthalmic venous plexus |
|
0 |
|
|
12986 |
324 |
BB.SHR-(D6Rat184-D6Rat3)/K |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405. |
blood triglyceride amount |
female |
84 days
| 15 |
|
176.99 |
mg/dl |
16.91 |
65.49 |
automated blood analysis |
opthalmic venous plexus |
0.0 |
0 |
|
|
70106 |
324 |
MWF-Chr 6SHR/Rkb |
serum triglyceride level |
control condition |
Schulz A, et al., J Am Soc Nephrol. 2007 Jan;18(1):113-21 |
blood triglyceride amount |
not specified |
168 days
| 19 |
|
108.85 |
mg/dl |
0.88 |
3.86 |
serum triglyceride analysis |
|
0.0 |
0 |
serum triglyceride analysis |
|
65385 |
117 |
FHH/EurMcwi |
serum triglyceride level |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
blood triglyceride amount |
male |
56 days
| 6 |
|
32.0 |
mg/dl |
1.4 |
3.43 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
99507 |
2318 |
FHH-Nr4a1m1Mcwi |
serum triglyceride level |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
blood triglyceride amount |
male |
56 days
| 6 |
|
30.0 |
mg/dl |
3.0 |
7.35 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
99508 |
2318 |
FHH/EurMcwi |
serum triglyceride level |
control condition |
Westbrook L, et al., J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10. |
blood triglyceride amount |
male |
112 days
| 6 |
|
50.0 |
mg/dl |
4.4 |
10.78 |
serum triglyceride analysis |
|
0.0 |
0 |
|
|
99511 |
2318 |
F344.ZUC-(Leprfa),OLETF-(D5Rat166-D5Rat90)/Tj |
serum triglyceride level |
control condition |
Kotoh J, et al., J Vet Med Sci. 2016 Aug 11. |
blood triglyceride amount |
male |
175 days
| 5 |
|
1851.46 |
mg/dl |
150.35 |
336.19 |
serum triglyceride analysis |
|
0.0 |
0 |
TG-E test kit (Wako Chem. LTD) |
|
98079 |
1978 |
SD-Ahrem2Sage |
serum triglyceride level |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
blood triglyceride amount |
male |
84 days
| 5 |
|
128.4 |
mg/dl |
26.0 |
58.14 |
automated serum analysis |
|
|
0 |
|
|
106403 |
3025 |
WOKW |
serum triglyceride level |
control condition |
Kloting I, et al., Biochem Biophys Res Commun 2001 Jun 1;284(1):150-6. |
blood triglyceride amount |
female |
196 days-224 days |
12 |
serial mean |
292.04 |
mg/dl |
|
|
automated blood analysis |
ophthalmic venous plexus |
0.0 |
0 |
Roche Cobas Mira Plus (Roche, Switzerland) |
average of measures taken at 196 days, 210 days and 224 days |
12423 |
251 |
Hsd:SD |
serum triglyceride level |
control condition (for 84 days) |
Harrill JA, et al., Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13. |
blood triglyceride amount |
female |
84 days
| 5 |
|
130.4 |
mg/dl |
35.4 |
79.16 |
automated serum analysis |
|
|
0 |
|
|
106404 |
3025 |